Solanezumab: Phase III start

This quarter, Eli Lilly will begin the 18-month, double-blind, placebo-controlled, international EXPEDITION3 trial to evaluate 400 mg IV solanezumab every 4 weeks in 2,100 patients with mild AD who have tested positive for amyloid pathology on a PET scan or cerebrospinal fluid result. The pharma declined to disclose how much it expects the trial will cost. ...